Publications: PD-L1

• Monitoring PD-L1 Expression on Circulating Tumor–Associated Cells in Recurrent Metastatic Non–Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy

• Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy

• AACR 2026: Monitoring PD-L1 in Tumor Macrophage Fusion Cells in Blood Identifies High PD-L1 Checkpoint Inhibitor Responses in Metastatic Breast Cancer

• SABCS 2025: Monitoring Upregulation of PD-L1 in Cancer Associated Macrophage-Like Cells in Blood Predicts Clinical Outcomes in Metastatic Cancer Patients Treated with PD-L1 Immunotherapies

• SABCS 2025: Prolonged survival following PD-L1/PD-1 immune checkpoint inhibitor therapy after leronlimab induced PD-L1 upregulation on cancer-associated macrophage-like cells and circulating tumor cells in patients with metastatic or locally advanced triple-negative breast cancer

• ASCO 2025: Monitoring PD-L1 Expression in Cancer-Associated Macrophage-Like Cells as Predictor of Clinical Outcomes in Metastatic Cancer Patients Treated with PD-L1 Immunotherapies

• ESMO 2025: Long Term Survival with Leronlimab Treatment in Patients with MetastaticTriple-Negative Breast Cancer (mTNBC)

• AACR 2025: Monitoring PD-L1 Expression in Cancer Associated Macrophage-Like Cells in Blood predicts Clinical Outcomes in Metastatic Cancer Patients Treated with PD-L1 Immunotherapies

• SABCS 2024:‍ ‍PD-L1 Upregulation in Circulating Tumor Associated Cells Predicts for Clinical Outcomes in a Phase 1/2 Clinical Trial Using SV-BR-1-GM Vaccine with the Check Point Inhibitor Retifanlimab in Metastatic Breast Cancer Patients, an Interim Analysis

• Polyploid Giant Cancer Cells 2024: PD-L1 Expression on Circulating Tumor Associated Macrophage Polyploids Predicts Patient Outcomes in Metastatic Breast Cancer

• Immunology 2023:  PD-L1 expression on circulating antigen presenting macrophages in blood predicts PFS & OS in an array of metastatic cancer types treated with PD-L1/PD-1 immunotherapies

• AACR 2023: Micronuclei in circulating stromal cells correlates with PD-L1 expression and predicts progression in metastatic breast cancer

• ASCO 2022: Monitoring PD-L1 Expression on Circulating Stromal Cells in Blood Predicts PFS and OS in Metastatic NSCLC Patients Treated with PD-L1/PD-1 Immunotherapy 

• ASCO 2022:Monitoring PD-L1 Expression on Circulating Tumor–Associated Cells in Recurrent Metastatic Non–Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy

• ASCO 2021: Sequential Monitoring of PD-L1 on Circulating Stromal Cells in Blood Predicts PFS in NSCLC Patients Undergoing Immunotherapy after Definitive Chemoradiation

• EDRN 2021: Sequential Monitoring of PD-L1 on Circulating Stromal Cells Predicts Outcomes in Localized Unresectable Stage II NSCLC Treated with Immunotherapy after Definitive Chemoradiation

• AACR 2020: Expression of PD-L1 on Circulating Stromal Cells Predicts Immunotherapy Response in Unresectable Non-Small Cell Lung Carcinoma After Definitive Chemoradiotherapy

• ASCO 2020: Sequential Monitoring of Circulating Stromal Cells from Blood is Predictive of Progression in NSCLC Patients Undergoing Anti-PD-L1 Therapy after Definitive Chemoradiation Therapy

• AACR 2016: Sequential tracking of PD-L1 expression and RAD50 induction in CTCs and circulating stromal cells of lung cancer patients during treatment with radiotherapy